Leukemia & Lymphoma Society Screen to Lead Program: (RFA) Request for Applications

The goal of this RFA is the development of small molecule for in vivo proof of concept studies in

disease relevant animal models for hematological malignancies. Proposals should include strong

scientific rationale for a new drug target in a hematological malignancy; provide information to assess

existing intellectual property or the potential for novel chemical space; demonstrate or explain how a

screening assay can be developed to accommodate a high volume of compounds; or indicate how a tractable

lead compound can be further developed. Up to six laboratories/projects will be selected during the

first year to participate in this new model of collaboration whereby LLS, grantee, sponsoring

institutions, investigators and appropriate service providers such as contract research organizations

("CRO") or core facilities at academic institutions, work together to develop compounds with the

potential to change the standard of care for patients with blood cancer.
http://www.lls.org/researchershealthcareprofessionals/academicgrants/screentolead/